companyName

extensiveId

feedTypes

includeDividend

includeEstimates

includeOverview

includeOwnership

snapshotDate

CompanyName_Query

companySlug

CompanyMetaData

CompanyContent_query

company

query CompanyName_Query(
  $companyName: String!
  $extensiveId: ID
  $snapshotDate: String
  $feedTypes: [ContentType!]!
  $includeEstimates: Boolean!
  $includeOverview: Boolean!
  $includeOwnership: Boolean!
  $includeDividend: Boolean!
) {
  ...CompanyMetaData_Ux1x9
  ...CompanyContent_query_3mc3wd
}

fragment AnalystData on Analyst {
  name
  pageUrl
  jobTitle
  imgUrl
}

fragment AuthorList on Content {
  __isContent: __typename
  id
  authors {
    __typename
    id
    name
    pageUrl
  }
}

fragment ChangePercentBlock_Company on Company {
  defaultInstrument {
    isin
    symbol
    priceData {
      diff1mPercentage
      diff1yPercentage
      diff3yPercentage
      diffFromStartPercentage
    }
    id
  }
}

fragment CompactFeed_3NXCcw on Query {
  compactFeed: feedContent(companySlug: $companyName, filter: {types: $feedTypes}) {
    edges {
      node {
        __typename
        id
        ...TeaserExtraCompact_content
        createdAt
        companies {
          viewerIsFollowing
          id
        }
      }
      cursor
    }
    pageInfo {
      endCursor
      hasNextPage
    }
  }
}

fragment CompanyAnalystQuery on Company {
  analysts {
    ...AnalystData
    name
    pageUrl
    jobTitle
    imgUrl
    id
  }
}

fragment CompanyContent_query_3mc3wd on Query {
  ...CompanyHeader_query_Ux1x9
  ...CompanyOwnership_query_Ux1x9 @include(if: $includeOwnership)
  ...CompanyFinancials_query_Ux1x9 @include(if: $includeEstimates)
  ...CompanyDividend_query_Ux1x9 @include(if: $includeDividend)
  ...CompanyInvestorConsensus_query_Ux1x9
  ...CompanyPageTop_query_Ux1x9 @include(if: $includeOverview)
  ...CompanyPageBottom_query_2bVJwf @include(if: $includeOverview)
  ...CompanyDisclaimer_query_Ux1x9
  ...Extensive_query_3u4Ry5
}

fragment CompanyCoverage_Company on Company {
  analysts {
    name
    id
  }
  isPayingCustomerOf
  isFormerCustomerOf
  isCorporateCustomer
  ...CompanyAnalystQuery
  defaultInstrument {
    ...TargetAndRecommendation_Company
    id
  }
}

fragment CompanyDescription_Company on Company {
  description
  websiteUrl
  name
}

fragment CompanyDisclaimer_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    name
    isPayingCustomerOf
    isFormerCustomerOf
    id
  }
}

fragment CompanyDividendER_query on Company {
  name
  defaultInstrument {
    estimateData {
      reportingCurrency
    }
    dividendTransactions: estimateTransactions(first: 1, includeQuarters: false) {
      actualized {
        year
        dividend
        dividendYield
        payoutPercentage
        sharePrice
      }
      estimates {
        year
        dividend
        dividendYield
        payoutPercentage
        sharePrice
      }
    }
    id
  }
}

fragment CompanyDividendNonER_query on Company {
  name
  defaultInstrument {
    nonERDividendSet: nonERCompanyNumberSet(includeQuarters: false) {
      year
      dividend
      dividendYield
      epsReported
      sharePrice
      currency
    }
    id
  }
}

fragment CompanyDividend_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    ...CompanyDividendER_query
    ...CompanyDividendNonER_query
    defaultInstrument {
      coreId
      id
    }
    id
  }
}

fragment CompanyFinancials_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    ...NonERCompanyNumbers_query
    ...CompanyNumbers_query
    defaultInstrument {
      coreId
      id
    }
    id
  }
}

fragment CompanyHeader_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    id
    companyInsref
    name
    viewerIsFollowing
    followersCount
    isCorporateCustomer
    hasPinpointData
    hasDividendHistory
    sector {
      sectorname
      industry
    }
    regions
    extensiveExists
    defaultInstrument {
      symbol
      priceData {
        tradeCurrency
        lastPrice
        diff1dPercentage
      }
      marketplace {
        name
      }
      estimates: estimateTransactions(first: 1, includeQuarters: false) {
        date
      }
      nonERCompanyNumberSet(first: 1, includeQuarters: false) {
        year
      }
      id
    }
    topOwners {
      holders {
        name
      }
    }
    transactions: insiderTransactions(filter: {types: [BUY, SELL, SUBSCRIPTION]}) {
      edges {
        node {
          date
          id
        }
      }
    }
  }
}

fragment CompanyInsiderTransactions on Company {
  name
  regions
  insiderTransactions(filter: {types: [BUY, EXERCISE_OF_SHARE_OPTION, PLEDGE, RECEPTION_OF_SHARE_PREMIUM, SELL, SUBSCRIPTION]}) {
    edges {
      node {
        insider
        position
        volume
        price
        date
        unit
        type
        relatedParty
        id
      }
    }
  }
}

fragment CompanyInvestorConsensus_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    name
    companyInsref
    id
  }
}

fragment CompanyMetaData_Ux1x9 on Query {
  company(companySlug: $companyName) {
    name
    description
    pageUrl
    defaultInstrument {
      estimateData {
        modelType
      }
      id
    }
    id
  }
}

fragment CompanyName_Slug on Company {
  slug
}

fragment CompanyNumbers_query on Company {
  name
  defaultInstrument {
    estimateData {
      modelType
      reportingCurrency
    }
    estimateTransactions(first: 1, includeQuarters: true) {
      comparisonIndexName
      actualized {
        year
        quarter
        revenue
        revenueGrowth
        ebitda
        ebitAdjusted
        ebitReported
        preTaxProfit
        netEarnings
        epsReported
        epsAdjusted
        dividend
        payoutPercentage
        roePercent
        roiPercent
        enterpriseValue
        bookValue
        marketCap
        gearingPercent
        equityRatio
        dividendYield
        totalCosts
        loanLosses
        balanceSheetTotal
        tangibleBook
        cet1
        rwa
        sharePrice
        sharesTotal
        nav
        navPerShare
        opexOfNav
        totalShareholderReturn
        comparisonIndexReturn
        netDebtTotalAsset
        quarterlySharePrice
      }
      estimates {
        year
        quarter
        revenue
        revenueGrowth
        ebitda
        ebitAdjusted
        ebitReported
        preTaxProfit
        netEarnings
        epsReported
        epsAdjusted
        dividend
        payoutPercentage
        roePercent
        roiPercent
        enterpriseValue
        bookValue
        marketCap
        gearingPercent
        equityRatio
        dividendYield
        totalCosts
        loanLosses
        balanceSheetTotal
        tangibleBook
        cet1
        rwa
        sharePrice
        sharesTotal
        nav
        navPerShare
        opexOfNav
        totalShareholderReturn
        comparisonIndexReturn
        netDebtTotalAsset
        quarterlySharePrice
      }
    }
    id
  }
}

fragment CompanyOverviewGraphs_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      companyTransactions: estimateTransactions(first: 1, includeQuarters: false) {
        actualized {
          year
          revenue
          ebitAdjusted
          epsAdjusted
          dividendYield
          navPerShare
          totalShareholderReturn
        }
        estimates {
          year
          revenue
          ebitAdjusted
          epsAdjusted
          dividendYield
          navPerShare
          totalShareholderReturn
        }
      }
      id
    }
    id
  }
}

fragment CompanyOwners on Company {
  regions
  topOwners {
    recordDate
    compareDate
    source
    holders {
      name
      capitalPercent
      votingPowerPercent
      positionChange
      totalSharesChange
      shareChange
      isNew
      isRemoved
    }
  }
}

fragment CompanyOwnership_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    name
    ...CompanyOwners
    ...CompanyInsiderTransactions
    id
  }
}

fragment CompanyPageBottom_query_2bVJwf on Query {
  ...GeneralFeed_data_3NXCcw
  ...CompactFeed_3NXCcw
  ...UpcomingEventsQuery_Ux1x9
  ...RiskRecommendMatrix_query_Ux1x9
  ...CompanyOverviewGraphs_query_Ux1x9
  ...NonERCompanyOverviewGraphs_query_Ux1x9
  company(companySlug: $companyName) {
    companyInsref
    ...ForumUpdates_Company
    defaultInstrument {
      coreId
      id
    }
    id
  }
  allFeed: feedContent(first: 1, companySlug: $companyName, filter: {hideUpcomingVideos: true}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  main: feedContent(first: 1, companySlug: $companyName, filter: {hideUpcomingVideos: true, types: [COMPANY_REPORT, EXTENSIVE_COMPANY_REPORT, ANALYST_COMMENT, VIDEO, ARTICLE]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  webcasts: feedContent(first: 1, companySlug: $companyName, filter: {hideUpcomingVideos: true, types: [WEBCAST]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  thirdPartyResearch: feedContent(first: 1, companySlug: $companyName, filter: {types: [THIRD_PARTY_COMPANY_REPORT]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  releases: feedContent(first: 1, companySlug: $companyName, filter: {types: [STOCK_EXCHANGE_RELEASE, PRESS_RELEASE]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
}

fragment CompanyPageTop_query_Ux1x9 on Query {
  ...StockChart_ChartQuery_Ux1x9
  ...LatestReports_query_Ux1x9
  company(companySlug: $companyName) {
    isFund
    name
    ...CompanyCoverage_Company
    ...CompanyName_Slug
    ...CompanyDescription_Company
    ...FundNumbers_Company
    ...ChangePercentBlock_Company
    ...KeyEstimateFigures_Company
    ...InvestmentCompanyKeyFigures_Company
    defaultInstrument {
      id
      estimateData {
        modelType
      }
    }
    analysts {
      name
      id
    }
    id
  }
  extensiveReport: feedContent(first: 1, companySlug: $companyName, filter: {types: [EXTENSIVE_COMPANY_REPORT]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  analysis: feedContent(first: 1, companySlug: $companyName, filter: {types: [COMPANY_REPORT, EXTENSIVE_COMPANY_REPORT], tagNames_nin: ["Mallisalkku", "Arvonluojat"]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  analysisArvonluojat: feedContent(first: 1, companySlug: $companyName, filter: {types: [COMPANY_REPORT, EXTENSIVE_COMPANY_REPORT], tagNames_nin: ["Mallisalkku"]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment Extensive_query_3u4Ry5 on Query {
  company(companySlug: $companyName) {
    extensive(extensiveId: $extensiveId, snapshotDate: $snapshotDate) {
      publishedAt
      pageUrl
      content {
        id
        title
        lang
        slug
        htmlBody
        publishedAt
        createdAt
        changedAt
        isOutdated
      }
    }
    id
  }
}

fragment ForumUpdates_Company on Company {
  name
  forum {
    threadUrl
    highlightedPosts {
      url
      author
      authorImgUrl
      text
      postedAt
      likesCount
    }
  }
}

fragment FundNumbers_Company on Company {
  defaultInstrument {
    isin
    symbol
    priceData {
      lastPrice
      ath
    }
    id
  }
}

fragment GeneralFeed_data_3NXCcw on Query {
  generalFeed: feedContent(first: 20, companySlug: $companyName, filter: {types: $feedTypes}) {
    edges {
      node {
        __typename
        id
        ...Teaser_content
        ...TeaserCompact_content
      }
      cursor
    }
    pageInfo {
      endCursor
      hasNextPage
    }
  }
}

fragment InvestmentCompanyKeyFigures_Company on Company {
  marketData {
    marketCap
  }
  defaultInstrument {
    priceData {
      tradeCurrency
      dailyTurnover
    }
    estimateData {
      modelType
    }
    estimateTransactions(first: 1, includeQuarters: true) {
      actualized {
        year
        quarter
        sharesTotal
        marketCap
        nav
        navPerShare
        dividendYield
        quarterlySharePrice
      }
      estimates {
        year
        quarter
        dividendYield
      }
    }
    id
  }
}

fragment KeyEstimateFigures_Company on Company {
  marketData {
    marketCap
  }
  defaultInstrument {
    priceData {
      tradeCurrency
      dailyTurnover
      lastPrice
      marketCap
    }
    sector
    fundamentalData {
      ebit
      eps
      sales
      dividend
    }
    estimateData {
      modelType
      estimates {
        firstEstimateYear {
          year
          bookValue
          netSales
          dividendA
          epsAdjusted
          ebitAdjusted
          hybridLoan
          noOfShares
          netDebt
          mvMinorities
          mvAssociated
          roePercent
        }
      }
    }
    estimatesSharePrice: estimateTransactions(first: 1) {
      estimates {
        sharePrice
      }
    }
    id
  }
}

fragment LatestReports_query_Ux1x9 on Query {
  extensiveReport: feedContent(first: 1, companySlug: $companyName, filter: {types: [EXTENSIVE_COMPANY_REPORT]}) {
    edges {
      node {
        __typename
        createdAt
        pageUrl
        id
      }
    }
  }
  analysis: feedContent(first: 1, companySlug: $companyName, filter: {types: [COMPANY_REPORT, EXTENSIVE_COMPANY_REPORT], tagNames_nin: ["Mallisalkku", "Arvonluojat"]}) {
    edges {
      node {
        __typename
        createdAt
        pageUrl
        id
      }
    }
  }
  analysisArvonluojat: feedContent(first: 1, companySlug: $companyName, filter: {types: [COMPANY_REPORT, EXTENSIVE_COMPANY_REPORT], tagNames_nin: ["Mallisalkku"]}) {
    edges {
      node {
        __typename
        createdAt
        pageUrl
        id
      }
    }
  }
}

fragment NonERCompanyNumbers_query on Company {
  name
  defaultInstrument {
    nonERNumberSet: nonERCompanyNumberSet(includeQuarters: true) {
      year
      quarter
      revenue
      ebitda
      ebitReported
      epsReported
      dividend
      sharesTotal
      roe
      roi
      enterpriseValue
      marketCap
      gearingRatio
      equityRatio
      dividendYield
      sharePrice
      currency
      evSales
      evEbitda
      evEbit
      pb
      netIncome
      ptp
    }
    id
  }
}

fragment NonERCompanyOverviewGraphs_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    defaultInstrument {
      overviewGraphsData: nonERCompanyNumberSet(includeQuarters: false) {
        year
        revenue
        ebitReported
        epsReported
        dividend
        dividendYield
        currency
      }
      id
    }
    id
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment RiskRecommendMatrix_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    defaultInstrument {
      riskData: estimateTransactions(first: 1) {
        businessRisk
        valuationRisk
      }
      id
    }
    id
  }
}

fragment StockChart_ChartQuery_Ux1x9 on Query {
  company(companySlug: $companyName) {
    isFund
    defaultInstrument {
      coreId
      id
      marketOpen
      marketClose
      marketplace {
        region
      }
      priceData {
        lastPrice
      }
      returns {
        day
        week
        month
        threeMonths
        sixMonths
        year
        threeYears
        fiveYears
        tenYears
        ytd
        total
      }
    }
    id
  }
}

fragment TargetAndRecommendation_Company on Instrument {
  estimateData {
    modelType
    researchCurrency
    estimates {
      date
      recommendation
      targetPrice
    }
  }
}

fragment TeaserCompact_content on Content {
  __isContent: __typename
  __typename
  id
  type
  title
  createdAt
  isPremium
  pageUrl
  lang
  companies {
    ...CompanyTagList
    id
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
  ...AuthorList
}

fragment TeaserExtraCompact_content on Content {
  __isContent: __typename
  id
  title
  createdAt
  pageUrl
  lang
  companies {
    name
    pageUrl
    viewerIsFollowing
    id
  }
}

fragment Teaser_content on Content {
  __isContent: __typename
  __typename
  id
  type
  title
  createdAt
  pageUrl
  imgUrl
  isPremium
  lang
  companies {
    ...CompanyTagList
    id
  }
  publishers {
    imgUrl
  }
  authors {
    __typename
    id
  }
  ... on AnalystComment {
    preview
  }
  ... on Article {
    preview
  }
  ... on CompanyReport {
    preview
  }
  ... on ThirdPartyCompanyReport {
    preview
  }
  ... on QA {
    preview
  }
  ... on Video {
    preview
    liveTime
    videoDuration
  }
  ... on Webcast {
    preview
    liveTime
  }
  ...AuthorList
  ...Reactions
}

fragment UpcomingEventsQuery_Ux1x9 on Query {
  company(companySlug: $companyName) {
    defaultInstrument {
      calendarEvents(first: 10) {
        edges {
          node {
            date
            type
            period
            id
          }
        }
      }
      id
    }
    id
  }
}


name

description

pageUrl

defaultInstrument

companyInsref

viewerIsFollowing

followersCount

isCorporateCustomer

hasPinpointData

hasDividendHistory

sector

regions

extensiveExists

topOwners

insiderTransactions

isPayingCustomerOf

isFormerCustomerOf

extensive

feedContent

Implantica

Implantica, Webcast, Q4'25

Implantica publishes Year-end Report, January - December 2025 (Q4)

Implantica presents the Year-end Report (Q4 2025) on February 25 at 15:00 CET

Implantica announces major public tender wins in Italy securing over EUR 1.2 million funding for RefluxStop®

Implantica strengthens market expansion as Italy's leading Careggi University Hospital in Florence introduces RefluxStop®

Implantica: RefluxStop® "Best in Class" at Japan Foregut Conference as 5-Year Data and Extensive Safety Cohort is Presented to 120 Leading Surgeons

Implantica: RefluxStop® takes center stage at 2025 European Foregut Society meeting

Implantica, Webcast, Q3'25

Implantica publishes Interim Report January - September 2025 (Q3)

Implantica presents the third quarter 2025 on October 31 at 15:00 CET

Implantica completes FDA 100-Day Meeting for RefluxStop® PMA application

Implantica Successfully Completes MDSAP Recertification Audit

Implantica steps up to close the treatment gap with RefluxStop® as main device competitor exits Europe and the UK

Implantica announces U.S. FDA has provided feedback on the final RefluxStop® PMA submission, Module 3

Implantica's RefluxStop® sparks strong excitement at the American Foregut Society meeting, ahead of pending US FDA approval

Implantica announces the payment of share rewards based on the AGM approved share-based incentive program as a directed share issue of own shares of the company without consideration

Implantica ramps-up production with 10,000 RefluxStop® units in preparation for U.S. launch, pending FDA PMA approval

Implantica, Audiocast, Q2'25

Implantica publishes Interim Report January - June 2025 (Q2)

Implantica finishes new multi-cavity production tool for RefluxStop® to support manufacturing ramp-up in the U.S. pending FDA approval

Implantica presents the second quarter 2025 on August 14 at 15:00 CEST

Implantica announces second publication of groundbreaking 5-year results from the landmark RefluxStop® clinical study

Implantica announces publication of the landmark RefluxStop® 5-year clinical study results demonstrating excellent long-term success

Implantica submits the last and final module 3 of the FDA PMA Application for RefluxStop® for US market approval

Implantica announces successful UK RefluxStop™ Users Meeting addressing growing demand after the final and positive UK NICE recommendations on use of RefluxStop in NHS public hospitals

First North Stockholm

Implantica operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes implantable medical instruments, which are also used for the treatment of diseases affecting the esophagus. In addition to the main business, related ancillary services are offered, particularly focused on eHealth. The business is operated globally with the largest presence in North America and Europe.

Implantica’s RefluxStop® sparked great enthusiasm at the American Foregut Society meeting in the United States ahead of the expected FDA approval. Medtech company Implantica presented its RefluxStop® implant, developed for the treatment of acid reflux, at the AFS annual meeting in Dallas, where over 600 leading surgeons and gastroenterologists showed strong interest in the device. Notably, the RefluxStop® panel discussion attracted nearly twice the planned number of participants. The device is in the final stages of the FDA approval process, and Implantica is already preparing for its US market launch by building infrastructure, inventory, and teams. RefluxStop® differs from traditional reflux surgeries because it does not encircle the esophagus, which reduces side effects. The method adheres to the modern anti-reflux principles recommended by the American Foregut Society. At the meeting, several top experts in the field – including Dr. John Lipham (USC), Prof. Peter Kahrilas (Northwestern), Dr. Tripp Buckley (UT Austin), Prof. Sebastian Schoppmann (Vienna) and Dr. Moustafa Elshafei (Germany) – highlighted the device’s promising long-term clinical results and innovative mechanism of action. Implantica’s founder and CEO, Dr. Peter Forsell, emphasized the enormous public health problem of acid reflux: 73 million people suffer from it in the United States alone. He believes that RefluxStop® has excellent potential to become the primary treatment method both in the United States and worldwide.  Implantica’s RefluxStop® sparks strong excitement at the American Foregut Society meeting, ahead of pending US FDA approval Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with over 1 billion sufferers, announces RefluxStop® was met with great enthusiasm and positive feedback among 600+ attendees at the 2025 American Foregut Society (AFS) Annual Meeting, further accelerating US pre-launch readiness. Anticipation for RefluxStop® in the US reached a fever pitch last week as the nation’s top foregut surgeons and gastroenterologists gathered in Dallas for the AFS Annual Meeting. Even though the US launch is yet to come, RefluxStop® was the topic of much sought-after independent presentations by the most esteemed surgeons. In addition, the dynamic RefluxStop® educational panel discussion attracted nearly 120 top surgeons and GI experts, well above the planned capacity, packing the room with great excitement to learn more about RefluxStop®. As the third and final module of the PMA application nears completion, we see a massive wave of interest emerging from surgeons in the US and worldwide, also witnessed at AFS. Accordingly, Implantica has started to build the necessary infrastructure, inventory, resources, and launch teams to deliver a speedy US rollout upon the PMA approval. Dr. John Lipham, USC Chief of the Division of Upper GI and General Surgery and Associate Professor of Surgery at the Keck School of Medicine and Past President of AFS moderated the well-attended RefluxStop® panel discussion where the excitement was palpable. The panel featured a lively discussion of the long-term data outcomes and the unique mechanism of action of the RefluxStop® procedure for treatment of acid reflux/GERD with an implant that does not encircle the esophagus. Dr. Lipham says, “I am very excited for RefluxStop as it comes closer to receiving FDA approval, given the impressive 5-year clinical study results consistent with real-world data from Europe. The way it treats GERD is an innovative approach that is aligned with the latest scientific principles of the Anti-Reflux Barrier (ARB) recommended by the American Foregut Society.” Dr. Lipham continues, “The AFS’s ARB approach not only focuses on the lower esophageal sphincter but also restores the other critical components of the body’s natural anti-reflux barrier, as is the case with the RefluxStop treatment approach. The RefluxStop does not encircle the esophagus, thus minimizing the side effects commonly associated with traditional anti-reflux surgeries.” The panel included experts: Dr. John Lipham, USC Chief of the Division of Upper GI and General Surgery and Associate Professor of Surgery at the Keck School of Medicine, Past President of AFS, served as the Foregut Cancer Program Director and Chief of USC Affiliated Academic Programs of Orange County   Dr. Peter Kahrilas, Professor of Medicine at Northwestern University   Dr. Tripp Buckley, Director of the Center for Heartburn & Esophageal Disorders Surgeon, Professor of Surgery at University of Texas at Austin   Professor of Surgery, Sebastian Schoppmann, MD, F.A.C.S., Head, Upper GI Service at the Medical University of Vienna, Austria, and   Dr. med. Moustafa Elshafei, Chief of General and Visceral Surgery at St. Elisabethen Hospital, Germany   Founder and CEO of Implantica, Dr. Peter Forsell adds, “I’m grateful for the dedication of independent surgeons like Prof. Schoppmann and Dr. med. Elshafei, who chose to collect and report RefluxStop® clinical data. Their profound work makes a big difference as we usher in a new generation of anti-reflux surgery with RefluxStop® leading the way.” Dr. Forsell continues, “Today, 73 million in the US suffer from acid reflux/GERD, it’s a very serious issue with an urgent need for innovative solutions like the RefluxStop® procedure. I am impressed by the enthusiastic welcome RefluxStop® has received from the AFS audience, made up of top US surgeons and gastroenterologists. With excellent long-term clinical outcomes of the RefluxStop® procedure, and such massive interest and demand from US and international surgeons, we feel confident that RefluxStop® has great potential to become the preferred treatment for GERD in the US and the rest of the world.”

Vahva on luotto firmalla, että FDA hyväksyntä tulee, kun on kehitetty uusi tuotantolaite jolla saadaan nopeammin valmistettua RefluxStopia. Implantica finishes new multi-cavity production tool for RefluxStop® to support manufacturing ramp-up in the U.S. pending FDA approval  logo  Implantica finishes new multi-cavity production tool for RefluxStop® to support manufacturing ramp-up in the U.S. pending FDA approval  Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with over 1 billion sufferers, announces completion and initial validation of a new RefluxStop® U.S. production tool as Implantica prepares for quickly increasing demand from the U.S. and markets worldwide, pending FDA approval. To ensure patients and surgeons across the globe will be able to access RefluxStop® quickly in the future, Implantica has developed and successfully completed initial testing on two new multi-cavity production tools for manufacturing of larger quantities of the RefluxStop® device. One tool will help support manufacturing ramp-up in Europe and one tool will be used to setup a new manufacturing site in the U.S. This crucial milestone comes after years of careful planning and rigorous development, representing Implantica’s deepening roots in the United States and commitment to serving future customers across the U.S. and the rest of the world. Dr. Peter Forsell, founder and CEO of Implantica, says, “After 1.5 years of production tool finalization for the U.S. market, final testing of the new tool in the U.S. is set to begin in the near-term. As we get closer to FDA approval of RefluxStop®, planning to manufacture the device domestically is a critical strategic step for Implantica. It will save shipping costs and eventual custom fees and streamline processes to allow for faster access to the therapy as demand quickly grows. These strategic preparations are key to supporting rapid adoption and scaling business in one of the world’s largest healthcare markets, driving long-term value for our shareholders.”

Tämä ketju on ollut hyvin hiljainen. Implantica on kuitenkin ollut hyvin kiinnostava taas viime kesästä alkaen, kun potilaiden seurannan tuloksia julkaistiin. Nyt FDA on antanut positiivista palautetta, koskien moduuli 2:ta hakuprosessissa. Tämä on kattavin ja tärkein moduuleista. Moduuli yksihän on hyväksytty. Implantica announces positive feedback received from U.S. FDA of the RefluxStop™ PMA Module 2 submission Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces that U.S. FDA has completed its review of the PMA Module 2 submission and provided its feedback, in which the company sees no barrier for responding. FDA has completed its review of the company’s second modular submission of its PMA, which contained the Clinical Data, Usability Testing, and Labeling information supporting RefluxStop™. FDA has provided Implantica with its written feedback on the content submitted, all of which the company considers to be minor. A response strategy has been identified for the questions raised, and the company sees no impediment to the overall PMA approval process based on FDA’s Module 2 feedback. Responses to the Module 2 feedback will be submitted in conjunction with the final Module 3 submission in the near term. Dr. Peter Forsell, Implantica’s founder, CEO, and the inventor of RefluxStop, says, "We are thankful for FDA for their review of Module 2 and are pleased to receive their positive feedback on our submission thus far. Module 2 includes the results of the RefluxStop™ clinical study and is by far the most important module for this PMA from our perspective. The 5-year outcomes in conjunction with data reported in the literature are extremely positive and indicate that RefluxStop™ may revolutionize this treatment field. Implantica will, in the near term, submit the last component of our PMA application (Module 3) and work with FDA to bring RefluxStop™ to the U.S. market as soon as possible.”

Implanticas Q3’25 webcast:                   Inderes              Implantica, Webcast, Q3'25 - Inderes    Time: 2025-10-31 15:00 Language: en Language: en Sector: Health care - Pharmaceuticals & Biotechnology Activity: Audiocast with teleconference

Toinen julkaisu RefluxStopin viiden vuoden seurannan tuloksista. Eihän tässä voi kuin odotella FDA hyväksynnän tuloksia, jotka toivottavasti tulee tässä lähiaikoina (autumn).                   implantica.com              Implantica announces second publication of groundbreaking 5-year results from...    Implantica AG (publ), a leading medtech company pioneering advanced implantable medical technologies, today announced the second peer-reviewed publication of the remarkable 5-year outcomes from its CE mark clinical study of RefluxStop®, a...                             Implantica announces second publication of groundbreaking 5-year results from the landmark RefluxStop® clinical study  07.08.2025  | Non regulatory  Implantica AG (publ), a leading medtech company pioneering advanced implantable medical technologies, today announced the second peer-reviewed publication of the remarkable 5-year outcomes from its CE mark clinical study of RefluxStop®, a revolutionary device for the treatment of acid reflux—a condition affecting over 1 billion people worldwide. The newly released publication focuses on long-term safety and effectiveness outcomes and complements the earlier 5-year report on food passageway-related outcomes. Both studies were published in the prestigious journal Surgical Endoscopy, jointly produced by the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) and the European Association for Endoscopic Surgery (EAES). The second publication, titled “Five-year clinical outcomes of RefluxStop surgery in the treatment of acid reflux: A prospective multicenter trial of safety and effectiveness,” provides the ultimate validation of RefluxStop®’s consistent and outstanding clinical performance. Key highlights include: 97.9% of patients were free from proton pump inhibitor (PPI) medication use at 5 years, compared to 100% of patients taking PPIs pre-RefluxStop® surgery.  No device-related adverse events reported over the entire 5-year study period.  Quality of life (GERD-HRQL scores) improved by a median of 90% (IQR), p<0.001.  Acid exposure time in lower essophagus (24h pH monitoring), the only objective acid reflux measure, improved by 90.4%, p<0.001.  Access the 5-year full publications: Effectiveness & Safety Outcomes  Food Passageway Outcomes  Dr. med. Joerg Zehetner of Klinik Beau-Site, Bern, Switzerland, who presented the study’s findings at the SAGES Scientific Conference in California, says: “RefluxStop® has demonstrated truly stellar results that significantly improve the quality of life for GERD patients. As a surgeon who has treated thousands of patients in Switzerland from all over the world, the safety profile is paramount to me—and this study confirms RefluxStop® as the safest and most effective surgical option for acid reflux sufferers available today. Over five years, there were no complications such as reherniations, migrations, or dislocations—confirmed via contrast-swallow imaging.” Dr. Zehetner further noted the superior patient experience: “It is very encouraging to see that RefluxStop has maintained its crucial anatomical position over time, resulting in excellent sustained long-term patient outcomes. Importantly, RefluxStop® uniquely restores the body’s natural anti-reflux barrier—offering unmatched long-term outcomes and safety as shown in this study. Also, postoperative swallowing difficulties were virtually eliminated—no patients required esophageal dilatation during the study, offering a major advantage compared to traditional GERD surgeries.” Dr. Peter Forsell, founder and CEO of Implantica, added: “These 5-year results confirm RefluxStop®’s strong potential to redefine the standard of care in GERD surgery. With nearly 50 RefluxStop® Centers of Excellence established across Europe, Implantica is rapidly growing its clinical and commercial infrastructure to support broader adoption. The company is now preparing for its U.S. market launch, pending FDA approval. As we approach the U.S. launch, we believe RefluxStop® is uniquely positioned to become the gold standard in surgical GERD treatment—offering superior patient outcomes, safety, and long-term cost-effectiveness. With FDA approval pending, global expansion underway, and increasing clinical momentum, we are focused on unlocking significant value for patients, providers, and shareholders alike.”

Tykkään tästä vertailusta toiseen hoitotapaan ja sen mahdollisiin haittavaikutuksien vs RefluxStop. Aika merkittävästi vähemmän haittavaikutuksia esiintyy RefluxStop vs Nissen  Implantica announces publication of the landmark RefluxStop® 5-year clinical study results demonstrating excellent long-term success  logo  Implantica announces publication of the landmark RefluxStop® 5-year clinical study results demonstrating excellent long-term success  Implantica AG (publ.), a medtech company at the forefront of treatment for acid reflux with its unique device RefluxStop®, a treatment field with 1 billion sufferers, announces the publication of RefluxStop’s extraordinary 5-year clinical data for food passageway-related outcomes in the prestigious journal, Surgical Endoscopy, an official journal of SAGES (American Gastrointestinal and Endoscopic Surgeons) and EAES (European Association For Endoscopic Surgery). The 5-year study results, where the first published article is about food passageway sequelae, show remarkable outcomes in relation to standard of care, supporting a paradigm shift in treatment of acid reflux sufferers. The 5 year and end of study results show: 97.9% of patients without any Adverse Event Dysphagia (difficulty swallowing)  97.9% of patients without any Adverse Event Odynophagia (painful swallowing)  95.7% of patients in the study with gas-bloating eliminated, improved or equivalent  100% of the study patients maintained the ability to belch or vomit  In addition to publication in Surgical Endoscopy, this study titled, “Food passageway-related sequelae in the RefluxStop prospective multicenter trial: Patient-centric outcomes of dysphagia, odynophagia, gas-bloating, and inability to belch and/or vomit at 5 years,” was the subject of a very successful SAGES 2025 (California, USA) oral presentation by Dr. med. Jörg Zehetner of Kinik Beau-Site Bern, Switzerland. Implantica CEO and founder, Dr. Peter Forsell, says, “A few data points from a large recently published literature review on standard of care Nissen fundoplication1 are helpful to provide an indirect comparison and offer some perspective on how extraordinary the RefluxStop® 5-year results are. Nissen fundoplication at 5 years presented with: Dysphagia in 28.9%, gas bloating in 52.7%, and inability to belch and vomit in 39.8%. The difference in outcomes are of such magnitude that they support an edict to a paradigm shift in acid reflux treatment. Publication of this study marks the dawn of a new era in the surgical treatment of GERD, one in which patients will have an innovative surgical treatment available that can restore the natural function of their body with minimal food passageway-related sequelae.” Dr. Forsell continues, “With a potential U.S. approval, pending FDA approval, in the near future, we are very excited about the opportunity to bring RefluxStop® to highly underserved GERD patients in the U.S. (where the disease affects 22-27% of the U.S. population) where RefluxStop’s unique non-encircling mechanism of action reduces side effects.”

Implantica submits the last and final module 3 of the FDA PMA Application for RefluxStop® for US market approval  logo  Implantica submits the last and final module 3 of the FDA PMA Application for RefluxStop® for US market approval  Implantica AG (publ.), a MedTech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop® for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces the submission of the third and final module of the RefluxStop® pre-market approval (PMA) application with the US Food and Drug Administration (FDA), along with responses to the second module. Implantica submitted the last and final Module 3 of the RefluxStop® PMA application together with the response to Module 2 review findings to FDA yesterday. Module 2, the clinical module, primarily addressed what we believed were minor findings. Module 3 is focused on tests of the product such as bench testing and biocompatibility testing for the RefluxStop® device. In line with the positive feedback in the FDA PMA application process so far, the latest RefluxStop® data submitted as part of the Module 2 response, as well as in the final Module 3, is quite robust and conclusive in Implantica’s opinion. We hope the newly submitted data and responses will not only continue to meet the stringent requirements for the PMA approval process but also exceed them. The continued process relies to a large extent now on FDA, which will guide Implantica in the coming steps. FDA’s feedback on Module 3 is expected sometime in the autumn. Inventor of RefluxStop®, Founder and CEO of Implantica, Dr. Peter Forsell, says, “I want to extend my gratitude to U.S. FDA for this thorough evaluation process of every facet of a new technology, such as RefluxStop®. Now more than ever, I believe we are on the cusp of a new generation of much needed surgical solutions for GERD with the potential to transform the standard of care for GERD patients in the U.S…” Dr Forsell continues, “This is a significant milestone for Implantica, one we all waited for. Undoubtedly, GERD is a grave and growing issue in the U.S. today, impacting approximately 22-27% of adults in the U.S. population. With over 1300 patients treated across nearly 50 centers in Europe and excellent long-term 5-year data results from the pivotal study, I believe RefluxStop® is poised to help these hugely underserved patients in the U.S. and worldwide in the years to come!”

Peter Forsell

Handelsbanken Fonder

Implantica

42.50 SEK

-2.86 %